Form 4: Immix Biopharma Director Jason Hsu Reports Stock Option Grant and Beneficial Ownership

Director Jason Hsu reports acquisition of stock options and details beneficial ownership of Immix Biopharma shares through direct and indirect holdings.

Summary

• On June 21, 2024, Jason Hsu, a director of Immix Biopharma, Inc., filed a Form 4 detailing changes in his beneficial ownership of the company's securities.
• The report indicates that Hsu was granted stock options to purchase 33,000 shares of common stock at an exercise price of $2.04 on June 11, 2024.
• These options vest in twelve equal monthly installments, contingent upon Hsu's continued service on the Board of Directors, and expire on June 11, 2034.
• Hsu directly owns 813,000 shares of Immix Biopharma common stock.
• He also indirectly owns 3,915,913 shares through VERITAS LIBERABIT VOS, LLC and 50,000 shares through Signature Collection Properties, LLC, for which he disclaims beneficial ownership except to the extent of his pecuniary interest.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock option grants and beneficial ownership, which is neither particularly positive nor negative.

Positives

• The grant of stock options to a director aligns their interests with those of shareholders, potentially incentivizing value creation.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track ownership changes and potential alignment of interests.

Stakeholder Impact

• Shareholders can monitor insider transactions to assess management's alignment with their interests.

Key Dates